Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Applovin Corporation (APP) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance

Applovin CorporationTrade
IDEXX Laboratories, Inc.Trade

Price performance (Past 24H)

Key statistics

Applovin Corporation vs IDEXX Laboratories, Inc. — how do they compare? Applovin Corporation trades at $313.49 (market cap $106.65B), while IDEXX Laboratories, Inc. trades at $573.57 (market cap $46.22B). The key difference: Applovin Corporation is far larger — about 2.3× IDEXX Laboratories, Inc.'s market cap, and IDEXX Laboratories, Inc. is trading nearer its 52-week high, Applovin Corporation nearer its low. Which is the better fit depends on your goals.

APPIDXX
Market Cap
$106.65B$46.22B
Sector
TechnologyHealth
52-Week High
$733.60$766.68
52-Week Low
$318.68$526.44
Enterprise Value
$107.11B$47.12B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Applovin Corporation

AppLovin (APP) trades at $313.50, down 7.52% in the last 24 hours, reflecting recent volatility after a Q2 2026 revenue miss. The stock is technically bearish with key support at $306, while fundamentals remain strong with 53% YoY revenue growth, 64.58% net income margin, and robust cash flow. Recent news highlights a Bank of America downgrade to Neutral, citing uncertainty around sustaining 30% long-term revenue growth, contributing to negative sentiment despite strong profitability.

The outlook is mixed: strong fundamentals and an 80.77% analyst buy rating with a $556.53 consensus price target suggest significant upside, but execution risks and growth sustainability concerns pose near-term headwinds. Investors face a trade-off between attractive valuation multiples and potential volatility from competitive and operational challenges in the ad-tech sector.

IDEXX Laboratories, Inc.

IDEXX Laboratories (IDXX) trades at $595.76, up 1.55% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $4.27 versus $3.94 expected, driven by 9% organic revenue growth. The company raised full-year EPS guidance to $14.69–14.94, reflecting robust demand in companion animal diagnostics. Valuation ratios remain elevated with a P/E of 41.23, supported by high profitability margins including a net income margin of 25.03% and ROE of 74.21%.

Outlook is positive given consistent earnings beats, international expansion, and product innovation, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $683.33 implies 14.7% upside, with 57% of analysts rating it Buy. Investors should weigh growth durability against high multiples.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Applovin Corporation

AppLovin provides a software platform for mobile app developers to market, monetize, and analyze their apps. Its AI-powered tools help developers grow their business by connecting them with global advertising networks.

Read more on APP

About IDEXX Laboratories, Inc.

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.

Read more on IDXX